RecruitingPhase 2NCT06589830

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

A Phase 2 Study to Evaluate TL938 Combined With Trastuzumab in Patients With HER2-positive Metastatic Colorectal Cancer

Sponsor

Suzhou Teligene Ltd.

Enrollment

80 participants

Start Date

May 13, 2025

Study Type

INTERVENTIONAL

Conditions

Colorectal Cancer Metastatic Advanced Colorectal Cancer

Summary

This is a Phase II trial designed to determine the optimal dose and evaluate the effectiveness of TL938 and trastuzumab in treating patients with HER2+ colorectal cancer that has metastasized or recurred and is inoperable.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called TL938 Capsules and a drug called Trastuzumab for people with advanced colorectal cancer and colorectal cancer metastatic. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.